| 000 | 01191 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250517154524.0 | ||
| 264 | 0 | _c20190319 | |
| 008 | 201903s 0 0 eng d | ||
| 022 | _a1536-3686 | ||
| 024 | 7 |
_a10.1097/MJT.0000000000000587 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMasuta, Pardeep | |
| 245 | 0 | 0 |
_aSGLT2 Inhibitors and Euglycemic Ketoacidosis. _h[electronic resource] |
| 260 |
_bAmerican journal of therapeutics _c |
||
| 300 |
_ae498-e500 p. _bdigital |
||
| 500 | _aPublication Type: Case Reports; Letter | ||
| 650 | 0 | 4 |
_aBlood Glucose _xanalysis |
| 650 | 0 | 4 |
_aCanagliflozin _xadverse effects |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xblood |
| 650 | 0 | 4 |
_aDiabetic Ketoacidosis _xblood |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGlucose _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInsulin _xtherapeutic use |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aSodium-Glucose Transporter 2 Inhibitors _xadverse effects |
| 700 | 1 | _aJohri, Geetanjali | |
| 700 | 1 | _aPaul, Manju | |
| 773 | 0 |
_tAmerican journal of therapeutics _gvol. 25 _gno. 4 _gp. e498-e500 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/MJT.0000000000000587 _zAvailable from publisher's website |
| 999 |
_c27204083 _d27204083 |
||